HDL and arteriosclerosis: beyond reverse cholesterol transport
Tóm tắt
Từ khóa
Tài liệu tham khảo
von Eckardstein, 1994, Physiological role and clinical relevance of high-density lipoprotein subclasses, Curr. Opin. Lipidol., 5, 404, 10.1097/00041433-199412000-00003
Huang, 1994, A solely apolipoprotein E containing plasma lipoprotein with electrophoretic gamma-mobility takes up cellular cholesterol, Proc. Natl. Acad. Sci. USA, 91, 1834, 10.1073/pnas.91.5.1834
von Eckardstein, 1995, Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma, Arterioscler. Thromb. Vasc. Biol., 15, 1755, 10.1161/01.ATV.15.10.1755
Gordon, 1989, High density lipoproteins—the clinical implication of recent studies, N. Engl. J. Med., 321, 1311, 10.1056/NEJM198911093211907
Assmann, 1992, Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study, Am. J. Cardiol., 70, 733, 10.1016/0002-9149(92)90550-I
Assmann, 1996, High density lipoprotein cholesterol as a predictor of coronary heart disease. The PROCAM experience and pathophysiological implication for reverse cholesterol transport, Atherosclerosis, 124, S11, 10.1016/0021-9150(96)05852-2
Genest, 1992, Familial lipoprotein disorders in patients with coronary disease, Circulation, 85, 2025, 10.1161/01.CIR.85.6.2025
Hergenc, 1999, Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals, Atherosclerosis, 145, 147, 10.1016/S0021-9150(99)00027-1
von Eckardstein, 2000, Prevention of coronary heart disease by raising of high density lipoprotein cholesterol, Curr. Opin. Lipidol., 11, 627, 10.1097/00041433-200012000-00010
Erren, 1999, Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries, Arterioscler. Thromb. Vasc. Biol., 19, 2355, 10.1161/01.ATV.19.10.2355
Ridker, 2001, High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease, Circulation, 103, 1813, 10.1161/01.CIR.103.13.1813
Bolibar, 2000, Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris, Thromb. Haemost., 84, 955, 10.1055/s-0037-1614155
Tall, 1998, An overview of reverse cholesterol transport, Europ. Heart J., 19, A31
Dietschy, 1993, Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, J. Lipid Res., 34, 1637, 10.1016/S0022-2275(20)35728-X
von Eckardstein, 2000, Acceleration of reverse cholesterol transport, Curr. Opin. Cardiol., 15, 348, 10.1097/00001573-200009000-00007
von Eckardstein, 2001, HDL and atherosclerosis: role of cholesterol efflux and reverse cholesterol transport, Arterioscler. Thromb. Vasc. Biol., 21, 13, 10.1161/01.ATV.21.1.13
Ross, 1973, Atherosclerosis and the arterial smooth muscle cell, Science, 180, 1332, 10.1126/science.180.4093.1332
Libby, 1985, Lipoprotein increase growth of mitogen-stimulated arterial smooth muscle cells, J. Cell Physiol., 124, 1, 10.1002/jcp.1041240102
Chen, 1986, Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in lipoprotein-deficient serum, J. Cell Physiol., 129, 207, 10.1002/jcp.1041290212
Cuthbert, 1989, Lipoproteins may provide fatty acids necessary for human lymphocyte proliferation by both low-density receptor-dependent and -independent mechanisms, J. Biol. Chem., 264, 13468, 10.1016/S0021-9258(18)80020-5
Fischer-Dzoga, 1976, Stimulation of proliferation in stationary primary cultures of monkey aortic smooth muscle cells: I. Effects of lipoprotein fractions of hyperlipemic serum and lymph, Exp. Mol. Pathol., 24, 515, 10.1016/0014-4800(76)90070-8
Fischer-Dzoga, 1976, Stimulation of proliferation in stationary primary cultures of monkey aortic smooth muscle cells: II. Effect of varying concentrations of hyperlipemic serum and low density lipoproteins of varying dietary fat origins, Atherosclerosis, 24, 515, 10.1016/0021-9150(76)90144-1
Björkerud, 1995, Growth-stimulating effect of lipoproteins on human arterial smooth-muscle cells and lung fibroblasts is due to apo B-containing lipoproteins, type LDL and VLDL, and requires LDL receptors, Biochim. Biophys. Acta, 1268, 237, 10.1016/0167-4889(95)00065-Z
Gospodarowicz, 1981, Factors controlling the proliferative rate, final cell density, and life span of bovine vascular smooth muscle cells in culture, J. Cell Biol., 89, 568, 10.1083/jcb.89.3.568
Resink, 1995, Low- and high density lipoproteins as mitogenic factors for vascular smooth muscle cell: Individual, additive and synergistic effects, J. Vasc. Res., 32, 328, 10.1159/000159107
Björkerud, 1994, Lipoproteins are primary mitogens and growth promoters for human arterial smooth muscle cells and lung fibroblasts in vitro, Arterioscler. Thromb. Vasc. Biol., 14, 288, 10.1161/01.ATV.14.2.288
Nofer, 2001, High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway, Thromb. Haemost., 85, 730, 10.1055/s-0037-1615660
Hahn, 1991, Modulation of gene expression by high and low density lipoproteins in human vascular smooth muscle cells, Biochem. Biophys. Res. Commun., 178, 1465, 10.1016/0006-291X(91)91058-K
Sachinidis, 1993, Lipoproteins induce expression of the early growth response gene-1 in vascular smooth muscle cells from rat, Biochem. Biophys. Res. Commun., 192, 794, 10.1006/bbrc.1993.1484
Walter, 1995, HDL3 stimulates multiple signaling pathways in human skin fibroblasts, Arterioscler. Thromb. Vasc. Biol., 15, 1975, 10.1161/01.ATV.15.11.1975
Drobnik, 1995, Activation of phosphatidylinositol-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients, Arterioscler. Thromb. Vasc. Biol., 15, 1369, 10.1161/01.ATV.15.9.1369
Walter, 1996, Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of the phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms, J. Clin. Invest., 98, 2315, 10.1172/JCI119043
Mendez, 1991, Protein kinase C as a mediator of high-density lipoprotein receptor-dependent efflux of intracellular cholesterol, J. Biol. Chem., 266, 104, 10.1016/S0021-9258(18)99196-9
Pörn, 1991, High-density lipoproteins induce a rapid and transient release of Ca2+ in cultured fibroblasts, Biochem. J., 279, 29, 10.1042/bj2790029
Honda, 1999, High density lipoprotein increases intracellular calcium levels by releasing calcium from internal stores in human endothelial cells, Atherosclerosis, 143, 299, 10.1016/S0021-9150(98)00302-5
Garver, 1997, Phosphoproteins regulated by the interaction of high-density lipoproteins with human skin fibroblasts, Arterioscler. Thromb. Vasc. Biol., 17, 2698, 10.1161/01.ATV.17.11.2698
Deeg, 1997, High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts, Arterioscler. Thromb. Vasc. Biol., 17, 1667, 10.1161/01.ATV.17.9.1667
Tournier, 1984, Rapid purification and activity of apolipoprotein C1 on the proliferation of bovine vascular endothelial cells in vitro, Biochim. Biophys. Acta, 804, 216, 10.1016/0167-4889(84)90152-6
Favre, 1989, Proliferative effect of high density lipoprotein (HDL) and HDL fractions (HDL1,2, HDL3) on virus transformed lymphoblastoid cells, Biochim. Biophys. Acta, 1013, 118, 10.1016/0167-4889(89)90039-6
Favre, 1993, High density lipoprotein 3 binding sites are related to DNA biosynthesis in the adenocarcinoma cell line A549, J. Lipid Res., 34, 1093, 10.1016/S0022-2275(20)37696-3
Ko, 1993, High density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells, Atherosclerosis, 99, 253, 10.1016/0021-9150(93)90027-R
Ishigami, 1998, Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase, J. Biol. Chem., 273, 156, 10.1074/jbc.273.32.20156
Ishigami, 2000, Apolipoprotein inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase, Arterioscler. Thromb. Vasc. Biol., 15, 1839
Nofer, 2000, Activation of phosphatidylinositol-specific phospholipase C (PI-PLC) by HDL-associated lysosphingolipids: Involvement in mitogenesis but not in cholesterol efflux, Biochemistry, 39, 199, 10.1021/bi001162a
Toborek, 1999, Endothelial cell functions. Relationship to atherogenesis, Basic. Res. Cardiol., 94, 295, 10.1007/s003950050156
Biegelsen, 1999, Endothelial function and atherosclerosis, Coronary Artery Dis., 10, 241, 10.1097/00019501-199906000-00006
Vanhoutte, 1997, Endothelial dysfunction and atherosclerosis, Eur. Heart J., 18, E19, 10.1016/S0195-668X(97)90005-1
Shimokawa, 1997, Endothelium and vascular injury in hypertension and atherosclerosis, 1007
Shimokawa, 1999, Primary endothelial dysfunction: atherosclerosis, J. Mol. Cell. Cardiol., 31, 23, 10.1006/jmcc.1998.0841
Ludmer, 1986, Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries, N. Engl. J. Med., 315, 1046, 10.1056/NEJM198610233151702
Hodgson, 1989, Direct vasoconstriction and endothelium-dependent vasodilation: mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries, Circulation, 79, 1043, 10.1161/01.CIR.79.5.1043
Werns, 1989, Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease, Circulation, 79, 287, 10.1161/01.CIR.79.2.287
Golino, 1991, Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients, N. Engl. J. Med., 324, 641, 10.1056/NEJM199103073241001
McFadden, 1991, Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina, N. Engl. J. Med., 324, 648, 10.1056/NEJM199103073241002
Sattar, 1998, The atherogenic lipoprotein phenotype and vascular endothelial dysfunction, Atherosclerosis, 138, 229, 10.1016/S0021-9150(98)00037-9
Toikka, 1999, Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men, Atherosclerosis, 147, 133, 10.1016/S0021-9150(99)00186-0
Zhang, 2000, Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease, Atherosclerosis, 149, 19, 10.1016/S0021-9150(99)00288-9
Li, 2000, Protective effect of high density lipoprotein on endothelium-dependent vasodilation, Int. J. Cardiol., 73, 231, 10.1016/S0167-5273(00)00221-7
Kaufmann, 2000, Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia, J. Am. Coll. Cardiol., 36, 103, 10.1016/S0735-1097(00)00697-5
Matsuda, 1993, High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation, Circ. Res., 72, 1103, 10.1161/01.RES.72.5.1103
Galle, 1994, Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein, Hypertension, 23, 556, 10.1161/01.HYP.23.5.556
Ota, 1997, Complexes of apoA-1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL, Am. Physiol., 273, H1215
Kuhn, 1991, Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity, Am. J. Cardiol., 68, 1425, 10.1016/0002-9149(91)90274-O
Zeiher, 1994, Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis, Circulation, 89, 2525, 10.1161/01.CIR.89.6.2525
Uittenbogaard, 2000, High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae, J. Biol. Chem., 275, 11278, 10.1074/jbc.275.15.11278
Tamagaki, 1996, Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells, Atherosclerosis, 123, 73, 10.1016/0021-9150(95)05774-9
Suc, 1997, HDL and Apo A prevent cell death of endothelial cells induced by oxidized LDL, Arterioscler. Thromb. Vasc. Biol., 17, 2158, 10.1161/01.ATV.17.10.2158
Sugano, 2000, High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis, Biochem. Biophys. Res. Commun., 272, 872, 10.1006/bbrc.2000.2877
Speidel, 1990, Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoproteins inhibit this cytotoxicity, Thromb. Res., 58, 251, 10.1016/0049-3848(90)90095-T
Pasqui, 2000, Complement activation in hypercholesterolemia, Nutr. Metab. Cardiovasc. Dis., 10, 137
Rosenfeld, 1983, Inhibition of the lytic action of cell-bound terminal complement-components by human high density lipoproteins and apoproteins, J. Clin. Invest., 71, 795, 10.1172/JCI110833
Packman, 1985, High-density lipoprotein and its apolipoproteins inhibit cytolytic activity of complement. Studies on the nature of inhibitory moiety, Biochim. Biophys. Acta, 812, 107, 10.1016/0005-2736(85)90527-9
Hamilton, 1991, The terminal complement protein C5b-9 augments binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells, J. Clin. Invest., 88, 1833, 10.1172/JCI115504
Hamilton, 1993, Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9, J. Biol. Chem., 268, 3632, 10.1016/S0021-9258(18)53740-6
Vakeva, 1994, High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma, Immunology, 82, 28
Schmiedt, 1998, Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits, Arterioscler. Thromb. Vasc. Biol., 18, 1790, 10.1161/01.ATV.18.11.1790
Vane, 1995, Pharmacodynamic profile of prostacyclin, Am. J. Cardiol., 75, 3A, 10.1016/S0002-9149(99)80377-4
Beitz, 1994, Is the anti-atherosclerotic potency of HDL modulated by the origin of HDL?, Prostaglandins Leukot. Essent. Fatty Acids, 50, 115, 10.1016/0952-3278(94)90093-0
Beitz, 1981, Differential influence of lipoproteins isolated from women and men on the activity of the PGI2 synthetase activity, Prostaglandins Med., 6, 515, 10.1016/0161-4630(81)90110-5
Beitz, 1980, Influence of human low density and high density lipoprotein cholesterol on the in vitro prostaglandin I2 synthase activity, Biochim. Biophys. Acta, 620, 352, 10.1016/0005-2760(80)90126-5
Fleisher, 1982, Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins, J. Biol. Chem., 257, 6653, 10.1016/S0021-9258(18)34477-6
Myers, 1996, Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification, Am. J. Physiol., 271, C1504, 10.1152/ajpcell.1996.271.5.C1504
Cockerill, 1999, High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2, Arterioscler. Thromb. Vasc. Biol., 19, 910, 10.1161/01.ATV.19.4.910
Vinals, 1997, HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2), Arterioscler. Thromb. Vasc. Biol., 17, 3481, 10.1161/01.ATV.17.12.3481
Jambou, 1993, Effect of human native low-density and high-density lipoproteins on prostaglandin production by mouse macrophage cell line P388D1: possible implications in the pathogenesis of atherosclerosis, Biochim. Biophys. Acta, 1168, 115, 10.1016/0005-2760(93)90274-D
Oravec, 1998, The effect of high density lipoprotein subfractions on endothelial eicosanoid secretion, Thromb. Res., 92, 65, 10.1016/S0049-3848(98)00106-6
Aoyama, 1990, Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris, Circulation, 81, 1784, 10.1161/01.CIR.81.6.1784
Yui, 1988, Serum prostacyclin (PGI2) stabilizing factor is identical to apolipoprotein A-I (Apo A-I): A novel function of apo A-I, J. Clin. Invest., 82, 803, 10.1172/JCI113682
Tsai, 1991, Regulation of PGI2 activity by serum proteins: serum albumin but not high density lipoprotein is the PGI2 binding and stabilising protein in human blood, Biochem. Biophys. Acta, 1115, 131, 10.1016/0304-4165(91)90021-8
Ong, 1994, Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells, Kidney Int., 46, 1315, 10.1038/ki.1994.400
Hu, 1994, High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells, J. Clin. Invest., 93, 1056, 10.1172/JCI117055
Horio, 1993, Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells, Atherosclerosis, 101, 185, 10.1016/0021-9150(93)90115-B
Sugiyama, 1995, Lipoproteins regulate C-type natriuretic peptide secretion from cultured vascular endothelial cells, Arterioscler. Thromb. Vasc. Biol., 15, 1968, 10.1161/01.ATV.15.11.1968
Poston, 1992, Expression of intercellular adhesion molecule-1 in atherosclerotic plaques, Am. J. Pathol., 140, 665
Van der Wal, 1992, Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions, Am. J. Pathol., 141, 1427
O'Brien, 1993, Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis, J. Clin. Invest., 92, 945, 10.1172/JCI116670
Printseva, 1992, Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3, Am. J. Pathol., 140, 889
Cybulsky, 1991, Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis, Science, 251, 788, 10.1126/science.1990440
Li, 1993, An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium, Arterioscler. Thromb., 13, 197, 10.1161/01.ATV.13.2.197
Kume, 1992, Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells, J. Clin. Invest., 90, 1138, 10.1172/JCI115932
Saxena, 1992, Lipoprotein lipase-mediated lipolysis of very low density lipoproteins increases monocyte adhesion to aortic endothelial cells, Biochem. Biophys. Res. Commun., 189, 1653, 10.1016/0006-291X(92)90267-O
Bauerle, 1994, Function and activation of NF-kappaB in the immune system, Ann. Rev. Immunol., 12, 141, 10.1146/annurev.iy.12.040194.001041
Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J. Clin. Invest., 88, 2039, 10.1172/JCI115532
Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler. Thromb. Vasc. Biol., 15, 1987, 10.1161/01.ATV.15.11.1987
Calabresi, 1997, Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins, Biochem. Biophys. Res. Commun., 238, 61, 10.1006/bbrc.1997.7236
Ashby, 1998, Factors influencing the ability of HDL to inhibit expression on vascular cell adhesion molecule-1 in endothelial cells, Arterioscler. Thromb. Vasc. Biol., 18, 1450, 10.1161/01.ATV.18.9.1450
Baker, 2000, Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression, J. Lipid Res., 41, 1261, 10.1016/S0022-2275(20)33434-9
Xia, 1999, High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL, J. Biol. Chem., 274, 143, 10.1074/jbc.274.46.33143
Theilmeier, 2000, HDL-associated PAF-AH reduces endothelial adhesiveness in apo E−/− mice, FASEB J., 14, 2032, 10.1096/fj.99-1029com
Dansky, 1999, Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium, J. Clin. Invest., 104, 31, 10.1172/JCI6577
Altieri, 1995, Structural recognition of a novel fibrinogen gamma chain sequence [117–133] by intercellular adhesion molecule-1 mediates leukocyte-endothelium interaction, J. Biol. Chem., 270, 696, 10.1074/jbc.270.2.696
Moudry, 1997, Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells, Shock, 7, 175, 10.1097/00024382-199703000-00004
Neufeld, 2000, High density lipoprotein inhibits fibrinogen binding on adenosine diphosphate-activated activated monocytes, Blood Coagul. Fibrinolysis, 11, 505, 10.1097/00001721-200009000-00001
Meade, 1980, Haemostatic function and cardiovascular death: early results of a prospective study, Lancet, 1, 1050, 10.1016/S0140-6736(80)91498-1
Meade, 1993, Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study, Lancet, 342, 1076, 10.1016/0140-6736(93)92062-X
Ruddock, 1994, Factor-VII activity and ischaemic heart disease: fatal and non-fatal events, QJM, 87, 403
Oseroff, 1989, Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease, J. Lab. Clin. Med., 113, 88
Dawson, 1992, The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review, Atherosclerosis, 95, 105, 10.1016/0021-9150(92)90014-8
Hellsten, 1992, Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: A cross-sectional study in Norsjo, Sweden, Eur. Heart J., 13, 57, 10.1093/oxfordjournals.eurheartj.a060048
Van der Bom, 1996, Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam study, Circulation, 95, 2623, 10.1161/01.CIR.95.12.2623
Lowe, 1998, Fibrin d-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischemic heart disease in the Caerphilly study, Thromb. Haemost., 79, 129, 10.1055/s-0037-1614231
Kaneko, 1994, Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins, Blood Coagul. Fibrinolysis, 5, 385
Rosenson, 1998, Effects of lipids and lipoproteins on thrombosis and rheology, Atherosclerosis, 140, 271, 10.1016/S0021-9150(98)00144-0
Carson, 1981, Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor, FEBS Lett., 132, 37, 10.1016/0014-5793(81)80422-X
Lesnik, 1993, Anti-coagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a), Arterioscl. Thromb., 13, 1066, 10.1161/01.ATV.13.7.1066
Epand, 1994, HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity, Arterioscler. Thromb., 14, 1775, 10.1161/01.ATV.14.11.1775
Moyer, 1998, Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes, Arterioscler. Thromb. Vasc. Biol., 18, 458, 10.1161/01.ATV.18.3.458
Rota, 1998, Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E, Blood, 91, 508, 10.1182/blood.V91.2.508
Griffin, 1999, High-density lipoprotein enhancement of anti-coagulant activities of plasma protein S and activated protein C, J. Clin. Invest., 103, 219, 10.1172/JCI5006
Mussoni, 1992, Hypertriglyceridemia and regulation of fibrinolytic activity, Arterioscler. Thromb., 12, 19, 10.1161/01.ATV.12.1.19
Juhan-Vague, 1996, Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European concerted action on thrombosis and diabetes, Circulation, 94, 2057, 10.1161/01.CIR.94.9.2057
Levin, 1994, Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells, Arterioscler. Thromb., 14, 438, 10.1161/01.ATV.14.3.438
Ren, 2000, Impact of anti-oxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells, Arterioscler. Thromb. Vasc. Biol., 20, 1688, 10.1161/01.ATV.20.6.1688
Pajkrt, 1997, Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia, Thromb. Haemost., 77, 303, 10.1055/s-0038-1655958
Naqvi, 1999, Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation, Am. J. Cardiol., 84, 1011, 10.1016/S0002-9149(99)00489-0
Aviram, 1983, Platelet interaction with high and low density lipoproteins, Atherosclerosis, 46, 259, 10.1016/0021-9150(83)90176-4
Aviram, 1983, Characterization of the effect of plasma lipoproteins on platelet function in vitro, Haemostasis, 13, 344
Hassall, 1983, The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin, Biochem. J., 216, 43, 10.1042/bj2160043
Nofer, 1998, HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs vie decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate, Arterioscler. Thromb. Vasc. Biol., 18, 861, 10.1161/01.ATV.18.6.861
Desai, 1989, Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation, J. Lipid Res., 30, 831, 10.1016/S0022-2275(20)38312-7
Riddell, 1997, Apolipoprotein E inhibits platelet aggregation through the l-Arginine: nitric oxide pathway, J. Biol. Chem., 272, 89, 10.1074/jbc.272.1.89
Chen, 1994, Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets, Life Sci., 55, 1815, 10.1016/0024-3205(94)90092-2
Riddell, 1999, Identification and characterization of LRP8 (apoER2) in human blood platelets, J. Lipid Res., 40, 1925, 10.1016/S0022-2275(20)34910-5
Higashihara, 1991, The role of apoE in inhibitory effects of apoE-rich HDL on platelet function, FEBS Lett., 282, 82, 10.1016/0014-5793(91)80449-D
Nazih, 1994, Protein kinase C-dependent desensitization of HDL3 activated phospholipase C in human platelets, Arterioscler. Thromb., 14, 1321, 10.1161/01.ATV.14.8.1321
Nofer, 1996, High density lipoproteins enhance the Na+/H+ antiport in human platelets, Thromb. Haemost., 75, 635, 10.1055/s-0038-1650335
Nazih, 1990, Phosphatidylcholine breakdown in HDL3 stimulated platelets, Thromb. Res., 59, 913, 10.1016/0049-3848(90)90115-S
Nazih, 1992, Pertussis toxin sensitive G-protein coupling of HDL receptor to phospholipase C in human platelets, Thromb. Res., 67, 559, 10.1016/0049-3848(92)90016-4
Nofer, 1995, HDL3 activates phospholipase D in normal but not in glycoprotein IIb/IIIa-deficient platelets, Biochem. Biophys. Res. Commun., 207, 148, 10.1006/bbrc.1995.1165
Curtiss, 1984, Interaction of plasma lipoproteins with human platelets, Blood, 64, 365, 10.1182/blood.V64.2.365.365
Koller, 1982, Specific binding sites on human blood platelets for plasma lipoproteins, Hoppe-Seyler Z. Physiol. Chem., 363, 395, 10.1515/bchm2.1982.363.1.395
Virgolini, 1992, Binding of 111In-labeled HDL to platelets form normolipemic volunteers and patients with heterozygous familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 12, 849, 10.1161/01.ATV.12.7.849
Koller, 1989, Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane, J. Biol. Chem., 264, 412, 10.1016/S0021-9258(18)63874-8
Pedreno, 2001, Platelet HDL(3) binding sites are not related to integrin alpha(IIb)beta(3) (GPIIb-IIIa), Atherosclerosis, 154, 23, 10.1016/S0021-9150(00)00442-1
Calvo, 1998, Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL, J. Lipid Res., 39, 777, 10.1016/S0022-2275(20)32566-9
Pedreño, 1999, Mechanisms for regulating platelet high density lipoprotein type 3 binding sites: evidence that binding sites are downregulated by a protein kinase C-dependent mechanism, Thromb. Res., 94, 33, 10.1016/S0049-3848(98)00196-0
Bierenbaum, 1979, Increased platelet aggregation and decreased high-density lipoprotein cholesterol in woman on oral contraceptives, Am. J. Obstet. Gynecol., 134, 638, 10.1016/0002-9378(79)90644-6
Lerch, 1998, Recostituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo, Thromb. Haemost., 80, 316, 10.1055/s-0037-1615194
Diaz, 1997, Anti-oxidants and atherosclerotic heart disease, N. Engl. J. Med., 337, 408, 10.1056/NEJM199708073370607
Holvoet, 1998, Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis, Atherosclerosis, 137, S33, 10.1016/S0021-9150(97)00305-5
Yla-Herttuala, 1999, Oxidized LDL and atherogenesis, Ann. N.Y. Acad. Sci., 874, 134, 10.1111/j.1749-6632.1999.tb09231.x
Hessler, 1979, LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle cells and endothelial cells in culture, Atherosclerosis, 32, 213, 10.1016/0021-9150(79)90166-7
Parthasarathy, 1990, High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein, Biochim. Biophys. Acta, 1044, 275, 10.1016/0005-2760(90)90314-N
Navab, 2000, Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3, J. Lipid Res., 41, 1495, 10.1016/S0022-2275(20)33462-3
Bowry, 1992, High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors, Proc. Natl. Acad. Sci., 89, 10316, 10.1073/pnas.89.21.10316
Sakai, 1996, The scavenger receptor serves as a route for internalization of lysophoysphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation, J. Biol. Chem., 271, 27346, 10.1074/jbc.271.44.27346
Witztum, 1998, Oxidized phospholipids and isoprostanes in atherosclerosis, Curr. Opin. Lipidol., 9, 441, 10.1097/00041433-199810000-00008
Hayek, 1995, HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice, Eur. J. Clin. Chem. Clin. Bioch., 33, 721
Gowri, 1999, Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL, Arterioscler. Thromb. Vasc. Biol., 19, 2226, 10.1161/01.ATV.19.9.2226
Garner, 1998, Oxidation of high density lipoproteins II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and apo A-II, J. Biol. Chem., 273, 6088, 10.1074/jbc.273.11.6088
von Eckardstein, 1991, Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoprotein A-I, C-II and C-III, J. Lipid Res., 32, 1465, 10.1016/S0022-2275(20)41914-5
Jonas, 1993, Structural and functional properties of natural and chemical variants of apolipoprotein A-I, Biochem. Biophys. Acta, 1166, 202, 10.1016/0005-2760(93)90098-T
Mackness, 1991, Paroxonase prevents accumulation of lipoperoxides in low-density lipoproteins, FEBS Lett., 286, 152, 10.1016/0014-5793(91)80962-3
Navab, 1996, The Yin and Yang of oxidation in the development of fatty streak, Arterioscl. Thromb. Vasc. Biol., 16, 831, 10.1161/01.ATV.16.7.831
Watson, 1995, Protective effect of high density lipoprotein-associated paroxonase. Inhibition of the biological activity of minimally oxidized low density lipoproteins, J. Clin. Invest., 96, 2882, 10.1172/JCI118359
Aviram, 2000, Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary artery diesease and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities, Circulation, 101, 2510, 10.1161/01.CIR.101.21.2510
Shih, 1996, Genetic-dietary regulation of serum paroxonase expression and its role in atherogenesis in a mouse model, J. Clin. Invest., 97, 1630, 10.1172/JCI118589
Navab, 1997, Mildly oxidized LDL induces an increased apolipoprotein J/paroxonase ratio, J. Clin. Invest., 99, 2005, 10.1172/JCI119369
Mackness, 2000, Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits, Biochem. Biophys. Res. Commun., 269, 232, 10.1006/bbrc.2000.2265
Hedrick, 2000, Short-term feeding of atherogenic diet results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism, Arterioscler. Thromb. Vasc. Biol., 20, 1946, 10.1161/01.ATV.20.8.1946
Hedrick, 2000, Glycation impaires high density lipoprotein function, Diabetologia, 43, 312, 10.1007/s001250050049
De Geest, 2000, Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase: comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis, Arterioscler. Thromb. Vasc. Biol., 20, 68, 10.1161/01.ATV.20.10.e68
Shih, 1998, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis, Nature, 394, 284, 10.1038/28406
Shih, 2000, Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis, J. Biol. Chem., 275, 17527, 10.1074/jbc.M910376199
Aviram, 1998, Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase, J. Clin. Invest., 101, 1581, 10.1172/JCI1649
Nagano, 1991, High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification, Proc. Natl. Acad. Sci. USA, 88, 6457, 10.1073/pnas.88.15.6457
Morel, 1994, Reduced cholesterol efflux to mildly oxidized high density lipoprotein, Biochem. Biophys. Res. Commun., 200, 408, 10.1006/bbrc.1994.1464
Rifici, 1996, Oxidation of high density lipoproteins: characterization and effects on cholesterol efflux from J774 macrophages, Biochim. Biophys. Acta, 1299, 87, 10.1016/0005-2760(95)00198-0
Takahashi, 1996, Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins, Biochem. Biophys. Res. Commun., 222, 453, 10.1006/bbrc.1996.0765
Humbert, 1993, The molecular basis of the human serum paraoxonase activity polymorphism, Nat. Gen., 3, 73, 10.1038/ng0193-73
Adkins, 1993, Molecular basis for the polymorphic forms of human paraoxonase arylesterase: glutamine or arginine at position 191 for the respective A or B alloenzymes, Am. J. Hum. Gen., 52, 598
Heinecke, 1998, Paraoxonase-gene polymorphism associated with coronary heart disease: support for the oxidative damage hypothesis?, Am. J. Hum. Gen., 62, 152, 10.1086/301691
Ruiz, 1995, Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes, Lancet, 346, 869, 10.1016/S0140-6736(95)92709-3
Sanghera, 1998, DNA polymorphism in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease, Am. J. Hum. Gen., 62, 36, 10.1086/301669
Serrato, 1995, A variant of human paraoxonase arylesterase (HUMPONA) gene is a risk factor for coronary heart disease, J. Clin. Invest., 96, 3005, 10.1172/JCI118373
Imai, 2000, Evidence for the association between paraoxonase gene polymorphism and atherosclerotic disease, Atherosclerosis, 149, 435, 10.1016/S0021-9150(99)00340-8
Mackness, 2000, Paraoxonase activity in two healthy populations with differing rates of coronary heart disease, Eur. J. Clin. Invest., 30, 4, 10.1046/j.1365-2362.2000.00580.x
Aubo, 2000, Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus, The REGICOR Investigators, Eur. Heart J., 21, 33, 10.1053/euhj.1999.1660
Leus, 2000, Paraoxonase gene polymorphism are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia, Atherosclerosis, 149, 371, 10.1016/S0021-9150(99)00324-X
Schmidt, 2000, MRI cerebral white matter lesions and paraoxonase PON1 polymorphism: three-year follow up of the Austrian stroke prevention study, Arterioscler. Thromb. Vasc. Biol., 20, 1811, 10.1161/01.ATV.20.7.1811
Bauters, 2000, Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin, Circulation, 101, 740, 10.1161/01.CIR.101.7.740
Sanghera, 1997, Genetic polymorphism of paraoxonase and the risk of coronary heart disease, Arterioscler. Thromb. Vasc. Biol., 17, 1067, 10.1161/01.ATV.17.6.1067
Badimon, 1989, High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbit, Lab. Invest., 60, 455
Badimon, 1990, Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit, J. Clin. Invest., 85, 1234, 10.1172/JCI114558
Neverov, 1997, HDL causes mesangial cell mitogenesis through a tyrosine kinase-dependent receptor mechanism, J. Am. Soc. Nephrol., 8, 1247, 10.1681/ASN.V881247
Wu, 1992, High density lipoproteins stimulate molecular weight 80 K protein phosphorylation in human trophoblast cells: evidence for a protein kinase C-dependent pathway in human placental lactogen release, Endocrinology, 131, 2935, 10.1210/en.131.6.2935